Azithromycin ophthalmic - InSite Vision

Drug Profile

Azithromycin ophthalmic - InSite Vision

Alternative Names: AzaSite; Azasite; AzaSite Xtra; azithromycin ophthalmic 1%; azithromycin ophthalmic 2%; ISV-401; ISV-405

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator InSite Vision
  • Developer Akorn; InSite Vision; Merck & Co
  • Class Antibacterials; Eye disorder therapies; Macrolides; Small molecules
  • Mechanism of Action Protein 50S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Conjunctivitis

Highest Development Phases

  • Marketed Infectious conjunctivitis
  • Preclinical Ophthalmic infections
  • Discontinued Blepharitis; Infectious keratitis

Most Recent Events

  • 10 Aug 2016 Nicox trasfers the rights for Azithromycin opthalmic in Europe, Africa and Middle East to a pan-European ophthalmic specialty pharmaceutical company
  • 15 Mar 2016 Biomarkers information updated
  • 03 Nov 2015 InSite Vision became an indirect wholly owned subsidiary of Sun Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top